FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2283-2285 November 20, 2008 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Vaccination with live attenuated virus can be highly effective for the induction of protective immunity and is critical in the prevention of once devastating epidemic diseases. Vaccines containing live attenuated virus offer more effective and lasting immunity at a much lower dose and, therefore, at a lower cost of production than inactivated vaccines.¹

However, such vaccines are not without drawbacks. First, the creation of a strain of virus that can be grown readily and replicates well enough in vivo to stimulate a protective immune response and yet does not cause disease is more art and guesswork than science. Indeed, vaccines . . . [Full Text of this Article]

Source Information

From the Department of Molecular Biology and Microbiology, Tufts University, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.